Novartis's U.S. patent for Entresto upheld by appeals court

Novartis said that its U.S. patent for Entresto was upheld by the U.S. Court of Appeals.

The Swiss pharmaceutical company said the court affirmed the validity of its patent on Entresto and combinations of sacubitril and valsartan.

The ruling comes after the company said in July 2023 that a U.S. District Court in Delaware had ruled the patent to be invalid.